IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 90M 180M 270M FY13: 0 FY14: 0 FY15: 0 FY16: 0 FY17: 0 FY18: 0 FY23: 1.2M FY24: 164.1M FY25: 263.5M FY13 FY14 FY15 FY16 FY17 FY18 FY23 FY24 FY25

Gross Profit Annual

0 35M 70M 105M FY23: 156K FY24: 70.8M FY25: 90.3M FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-600M -400M -200M 0 200M 400M 600M FY16: -53.6M FY17: -92.9M FY18: -128.3M FY19: -206.9M FY20: -261.9M FY21: -342.7M FY22: -398.9M FY23: -460.6M FY24: -395.3M FY25: -403.4M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-600M -400M -200M 0 200M 400M 600M FY16: -52.9M FY17: -92.1M FY18: -123.6M FY19: -197.6M FY20: -259.6M FY21: -342.3M FY22: -395.9M FY23: -444M FY24: -372.2M FY25: -391M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 60M 120M 180M FY23: 1M FY24: 93.2M FY25: 173.2M FY23 FY24 FY25

Operating Cash Flow Annual

-450M -300M -150M 0 150M 300M 450M FY16: -32.7M FY17: -78.7M FY18: -101.2M FY19: -158.9M FY20: -205.1M FY21: -227.9M FY22: -292.8M FY23: -361.8M FY24: -353M FY25: -302.4M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-450M -300M -150M 0 150M 300M 450M FY16: -34.2M FY17: -79.7M FY18: -102.4M FY19: -165.8M FY20: -251.9M FY21: -265.5M FY22: -313.2M FY23: -384.1M FY24: -364M FY25: -336.2M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 150K 300K 450K FY19: 124.3K FY20: 138.3K FY21: 153.4K FY22: 159.3K FY23: 235.1K FY24: 289.9K FY25: 357.3K FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '10: -0.02 Q1 '11: -0.03 Q2 '11: -0.18 Q3 '11: -0.24 Q4 '11: -0.34 Q1 '12: 7.06 Q2 '12: 7.21 Q3 '12: 6.42 Q4 '13: -7.63 Q1 '14: -6.46 Q2 '14: -2.36 Q3 '14: -1.81 Q4 '14: -0.48 Q1 '15: -0.51 Q2 '15: -0.56 Q3 '15: -0.61 Q4 '15: -0.61 Q1 '16: -0.61 Q2 '16: -0.70 Q3 '16: -1.69 Q4 '16: -1.77 Q1 '17: -1.96 Q2 '17: -2.10 Q3 '17: -1.30 Q4 '17: -1.41 Q1 '18: -1.39 Q2 '18: -1.36 Q3 '18: -1.37 Q4 '18: -1.28 Q1 '19: -1.27 Q2 '19: -1.31 Q3 '19: -1.35 Q4 '19: -1.58 Q1 '20: -1.83 Q2 '20: -1.92 Q1 '22: -2.29 Q2 '22: -2.39 Q3 '22: -2.47 Q4 '22: -2.48 Q1 '23: -2.40 Q4 '11 Q1 '14 Q2 '15 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q1 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.